Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 23,100 shares of the business’s stock in a transaction that occurred on Tuesday, November 8th. The shares were purchased at an average price of $9.22 per share, for a total transaction of $212,982.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $28,295,728.22. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, November 9th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The stock was bought at an average price of $9.33 per share, for a total transaction of $50,382.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was bought at an average price of $9.48 per share, for a total transaction of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was bought at an average price of $9.49 per share, for a total transaction of $94,900.00.
  • On Monday, October 31st, Phillip Md Et Al Frost bought 11,800 shares of Opko Health stock. The stock was bought at an average price of $9.43 per share, for a total transaction of $111,274.00.
  • On Friday, October 28th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was bought at an average price of $9.46 per share, for a total transaction of $94,600.00.
  • On Thursday, October 27th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was bought at an average price of $9.36 per share, for a total transaction of $93,600.00.
  • On Wednesday, October 26th, Phillip Md Et Al Frost bought 5,600 shares of Opko Health stock. The stock was bought at an average price of $9.27 per share, for a total transaction of $51,912.00.
  • On Tuesday, October 25th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The stock was bought at an average price of $9.38 per share, for a total transaction of $33,768.00.
  • On Monday, October 24th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was bought at an average price of $9.50 per share, for a total transaction of $17,100.00.
  • On Friday, October 21st, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was bought at an average price of $9.38 per share, for a total transaction of $16,884.00.

Opko Health Inc. (NYSE:OPK) opened at 9.38 on Friday. The stock has a market cap of $5.16 billion and a PE ratio of 39.25. The firm has a 50 day moving average of $9.89 and a 200-day moving average of $9.89. Opko Health Inc. has a 12-month low of $7.12 and a 12-month high of $11.85.

Opko Health (NYSE:OPK) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). The company earned $298 million during the quarter, compared to analysts’ expectations of $322 million. Opko Health’s revenue was up 108.4% on a year-over-year basis. During the same period last year, the firm posted $0.25 earnings per share. On average, analysts expect that Opko Health Inc. will post ($0.06) earnings per share for the current year.

Insider Buying and Selling by Quarter for Opko Health (NYSE:OPK)

OPK has been the topic of a number of recent research reports. Jefferies Group reiterated a “hold” rating on shares of Opko Health in a research note on Wednesday, August 17th. JPMorgan Chase & Co. set a $14.00 price objective on shares of Opko Health and gave the company a “buy” rating in a research note on Tuesday, August 9th. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, October 25th. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Opko Health in a research note on Monday, October 10th. Finally, TheStreet downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Opko Health currently has an average rating of “Buy” and a consensus target price of $13.20.

Several large investors have recently added to or reduced their stakes in the stock. Janus Capital Management LLC increased its stake in Opko Health by 0.6% in the second quarter. Janus Capital Management LLC now owns 15,800 shares of the company’s stock worth $148,000 after buying an additional 100 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in shares of Opko Health by 1.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 22,945 shares of the company’s stock worth $214,000 after buying an additional 261 shares during the period. Gilman Hill Asset Management LLC boosted its position in shares of Opko Health by 0.6% in the second quarter. Gilman Hill Asset Management LLC now owns 46,661 shares of the company’s stock worth $436,000 after buying an additional 298 shares during the period. Fisher Asset Management LLC boosted its position in shares of Opko Health by 1.1% in the third quarter. Fisher Asset Management LLC now owns 38,229 shares of the company’s stock worth $405,000 after buying an additional 403 shares during the period. Finally, Suntrust Banks Inc. boosted its position in shares of Opko Health by 4.3% in the third quarter. Suntrust Banks Inc. now owns 12,059 shares of the company’s stock worth $126,000 after buying an additional 500 shares during the period.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.